Literature DB >> 27428255

Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis.

Sinem Nalbantoglu1, Mones Abu-Asab2, Ming Tan3, Xuemin Zhang3, Ling Cai3, Hakima Amri1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the rapidly growing forms of pancreatic cancer with a poor prognosis and less than 5% 5-year survival rate. In this study, we characterized the genetic signatures and signaling pathways related to survival from PDAC, using a parsimony phylogenetic algorithm. We applied the parsimony phylogenetic algorithm to analyze the publicly available whole-genome in silico array analysis of a gene expression data set in 25 early-stage human PDAC specimens. We explain here that the parsimony phylogenetics is an evolutionary analytical method that offers important promise to uncover clonal (driver) and nonclonal (passenger) aberrations in complex diseases. In our analysis, parsimony and statistical analyses did not identify significant correlations between survival times and gene expression values. Thus, the survival rankings did not appear to be significantly different between patients for any specific gene (p > 0.05). Also, we did not find correlation between gene expression data and tumor stage in the present data set. While the present analysis was unable to identify in this relatively small sample of patients a molecular signature associated with pancreatic cancer prognosis, we suggest that future research and analyses with the parsimony phylogenetic algorithm in larger patient samples are worthwhile, given the devastating nature of pancreatic cancer and its early diagnosis, and the need for novel data analytic approaches. The future research practices might want to place greater emphasis on phylogenetics as one of the analytical paradigms, as our findings presented here are on the cusp of this shift, especially in the current era of Big Data and innovation policies advocating for greater data sharing and reanalysis.

Entities:  

Mesh:

Year:  2016        PMID: 27428255      PMCID: PMC4968342          DOI: 10.1089/omi.2016.0059

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  47 in total

1.  Phyloproteomics: what phylogenetic analysis reveals about serum proteomics.

Authors:  Mones Abu-Asab; Mohamed Chaouchi; Hakima Amri
Journal:  J Proteome Res       Date:  2006-09       Impact factor: 4.466

2.  The nature of diseases: evolutionary, thermodynamic and historical aspects.

Authors:  G F Azzone
Journal:  Hist Philos Life Sci       Date:  1996       Impact factor: 1.205

3.  Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.

Authors:  Michaela Aichler; Christopher Seiler; Monica Tost; Jens Siveke; Pawel K Mazur; Patricia Da Silva-Buttkus; Detlef K Bartsch; Peter Langer; Sara Chiblak; Anna Dürr; Heinz Höfler; Günter Klöppel; Karin Müller-Decker; Markus Brielmeier; Irene Esposito
Journal:  J Pathol       Date:  2012-01-17       Impact factor: 7.996

4.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

5.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Authors:  E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

6.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

7.  Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis.

Authors:  Kosuke Tobita; Hiroshi Kijima; Shoichi Dowaki; Hiroyuki Kashiwagi; Yasuo Ohtani; Yasuhisa Oida; Hitoshi Yamazaki; Masato Nakamura; Yoshito Ueyama; Makiko Tanaka; Sadaki Inokuchi; Hiroyasu Makuuchi
Journal:  Int J Mol Med       Date:  2003-03       Impact factor: 4.101

8.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

9.  Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.

Authors:  Brian E Kadera; Dharma B Sunjaya; William H Isacoff; Luyi Li; O Joe Hines; James S Tomlinson; David W Dawson; Matthew M Rochefort; Graham W Donald; Barbara M Clerkin; Howard A Reber; Timothy R Donahue
Journal:  JAMA Surg       Date:  2014-02       Impact factor: 14.766

10.  Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study.

Authors:  E Matano; P Tagliaferri; A Libroia; V Damiano; A Fabbrocini; S De Lorenzo; A R Bianco
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  1 in total

Review 1.  An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential.

Authors:  Nurul Akmaryanti Abdullah; Nur Fariesha Md Hashim; Aula Ammar; Noraina Muhamad Zakuan
Journal:  Molecules       Date:  2021-02-03       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.